Cited by 14Health Systems, Economic Evaluations, Quality of LifeDiabetes Management and ResearchDiabetes Treatment and Management

Cost-Effectiveness Analysis of Flash Glucose Monitoring System for People with Type 2 Diabetes Receiving Intensive Insulin Treatment

Open access
Ajjan, Ramzi, Bilir, S. Pinar, Hellmund, Richard, Souto, Diana·2022·Diabetes Therapy

Abstract

AIMS: For people with type 2 diabetes (T2D) on intensive insulin therapy, the use of flash continuous glucose monitoring ("flash monitoring") is associated with improved average glucose control and/or reduced hypoglycemic exposure. This study assessed the cost-effectiveness of flash monitoring versus traditional blood glucose monitoring (BGM) in people with T2D using intensive insulin in the United Kingdom (UK). METHODS: The IQVIA CORE Diabetes Model (IQVIA CDM; v9.0) was used to analyze the impact of flash monitoring versus BGM over a 40-year time horizon from the UK payer perspective. Model inputs included baseline characteristics, intervention effects, resource utilization, costs, and utilities, based on recently published literature and national databases. UK National Health Service reimbursed costs of flash monitoring and BGM were used. An intervention-related health utility was obtained from a time trade-off study. Alternative scenarios were explored to assess the impact of key assumptions on base case results. RESULTS: In base-case analysis, flash monitoring compared with BGM resulted in an incremental cost of £5781 and an additional 0.47 quality-adjusted life years (QALYs). This provides an incremental cost-effectiveness ratio (ICER) of £12,309/QALY. HbA1c and the intervention-related health utility were the key drivers of differentiation. All scenario analyses, including different discount rates, time horizons, effects on HbA1c and on the intervention-related health utility, as well as glycemic emergencies, generated ICERs of less than £20,000 per QALY. CONCLUSIONS: The consistent results across base case and a range of scenario analyses indicate that long-term flash glucose monitoring use is cost-effective compared with BGM in a UK population of T2D on intensive insulin therapy based on updated clinical effects and a cost-effectiveness threshold of £20,000-30,000 per QALY.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-022-01325-w

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For T2D patients not on insulin therapy, isCGM offers convenience while meeting glycemic monitoring needs, with potential long-term cost benefits.

    “For T2D patients not on insulin therapy, isCGM offers convenience while meeting glycemic monitoring needs [25], with potential long‐term cost benefits [48].”

    From Effectiveness of Wearable Devices for Diabetes Management: An Overview of Systematic Reviews and Meta‐Analyses (2026) · cites this paper as [48]

    The Conclusions state that long-term flash glucose monitoring is cost-effective and that remote monitoring may yield cost savings. But the analysis concerns people with T2D receiving intensive insulin therapy; it does not establish potential long-term cost benefits for the non-insulin-treated patients named in the citing sentence. The convenience and monitoring-needs clause is attached to a different citation. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 40 · Cited by 14

Research works printed but not linked: 1

  1. [24]National Institute of Health and Care Excellence - Guide to the methods of technology appraisal 2013 (PMG9). 2013. (Accessed Apr, 2018, at https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781). 27905712

Authors
Ajjan, R., Bilir, S. P., Hellmund, R., & Souto, D.
Affiliations
  • University of Leeds (GB)
  • IQVIA (United States) (US)
  • Abbott Diabetes Care (United States) (US)
Corresponding author
Hellmund, Richard
Venue
Diabetes Therapy
Published
2022-10-26
Volume
13
Issue
11-12
Pages
1933-1945
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4307573094
Cited by
14
References
40
Citations by year
2026: 3 · 2025: 5 · 2024: 6
FWCI
2.21
Type
journal article
Language
en
Open access
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Abbott Diabetes Care
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
flash glucose monitoring, continuous glucose monitoring, type 2 diabetes, intensive insulin therapy, cost-effectiveness, blood glucose monitoring, HbA1c, hypoglycemia, quality-adjusted life years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review